Dan Schell articles
-
A Closer Look At Precision Medicine Clinical Trials
1/9/2024
As Sumitomo Pharma America (SMPA) starts to focus more on precision medicine, the sponsor is encountering a new set of challenges when it comes to running clinical trials.
-
How Re-educating PIs Can Improve Clinical Trial Diversity
12/14/2023
Usually, discussions around ways to improve diversity in clinical trials focus on changing traditional protocol-design processes, finding and tapping into larger pools of diverse patients, educating patients on the value of clinical trials — that type of stuff. You don't normally hear people talking about re-educating physicians as a solution.
-
Can Data Help Improve Diversity In Clinical Trials?
12/7/2023
Denise Bronner Ph.D., director of diversity, equity, and inclusion in clinical trials at Johnson & Johnson Innovative Medicine (JJIM) talks about some of the types of datasets that can be leveraged to improve diversity in clinical trials.
-
My Opinion: CRCs, CRAs, and CTMs Have It Tough
11/27/2023
With 20+ years as a CRC, CRA, clinical trial manager, and project manager, Tiffany Ashton, MAS, CCRA talks about how difficult it can be working in some of these roles in today’s clinical trials industry.
-
Bayer Launches Investigator-Sponsored Collaborative Studies
11/10/2023
Bayer added three Phase 3 trials to its MOONRAKER clinical development program for the study of Kerendia (finerenone) as a potential treatment for heart failure. Overall, the goal for the program is to enroll 15,000 participants.